Drugs / Oxiracetam
Oxiracetam
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT04205565 Comparator | Sep 2019 → Aug 2024 | brain injury | Nanjing Yoko Biomedical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oxiracetam | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04205565 ↗ |
| Known as | CGP 21690E | ChEMBL registry synonym — accepted as the source's own label CHEMBL36633 ↗ |
| Known as | GNF-PF-1005 | ChEMBL registry synonym — accepted as the source's own label CHEMBL36633 ↗ |
| Modality | Small molecule | — CHEMBL36633 ↗ |
| Route | Intravenous | “Oxiracetam injection, 6 vials, once a day, IV.” NCT04205565 ↗ |